Fourteen clinical trials were revised, to provide the level of evidence for neuropathy
Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors
Key Insights Fatigue is a common but usually temporary side effect during the initial weeks or dose changes in GLP-1 therapy, caused largely by rapid calorie deficit, dehydration, and metabolic adjustments. Maintaining steady energy requires prioritising nutrient-dense meals rich in protein and complex carbohydrates, staying well hydrated, and managing electrolyte balance, which helps mitigate tiredness and supports overall metabolism. Gentle physical activity and good sleep hygiene are critical lifestyle adjustments that improve circulation, mood, and energy levels without overtaxing the body during the drug adaptation period. Persistent, worsening, or debilitating fatigue should prompt medical evaluation to exclude other causes, reassess medication dosing, and ensure safe continuation of GLP-1 therapy under healthcare supervision. Frequently asked questions Why do GLP-1 medications cause fatigue
European Journal of Nutrition, 61 , 413-428
The legal and ethical landscape proves complex - all performance peptides face WADA bans and athletic organization prohibitions making them inappropriate for tested competitive athletes despite legal status for personal research use in most jurisdictions
These findings might lay the foundation for the potential regenerative treatment of patients with chronic stroke
